Menarini group's elacestrant granted priority review by the u.s. fda for patients with er+/her2- advanced or metastatic breast cancer

Florence, italy & new york--(business wire)-- #fda--the menarini group and its subsidiary stemline therapeutics announce that fda grants priority review of elacestrant for metastatic breast cancer.

RDUS Ratings Summary

RDUS Quant Ranking